Conference «BIOTEHMED» (Gelendzhik, Russia)
While attending a conference BIOTEHMED- 2016 Russian Minister of Health Veronika Skvortsova, together with the head of the Russian Ministry of Industry and Trade Denis Manturov and the General Director of the State Corporation Rostec Sergei Chemezov visited the stand of "Refnot- Farm", where drugs of cytokines were presented - Ingaron® and Refnot®.
Date: 26.09-27.09.2016More...
XXIII Congress of the European Association for Cranio Maxillo-Facial Surgery. London, United Kingdom
As part of the 23rd International Congress of the European Association for cranio-maxillo-facial surgery team of Russian scientists presented the report «The use of the drug Refnot® (α-tumor necrosis factor-thymosin-α1) in patients with disseminated skin melanoma».
Date: 31.09-16.09.2016More...
The XII Nationwide Scientific and Practical Conference titled “Domestic Antitumor Products” took place in Moscow on 31.03-01.04 2015 in Russian Nikolai Blokhin Cancer Research Center.
A symposium was held as part of the conference, dedicated to the research and application results of Refnot medical product (recombinant fused protein of tumor necrosis factor and thymosine-alpha1)
Date: 31.03-01.04 2015More...
Moscow, International Medical Congress titled “PALLIATIVE MEDICINE IN THE HEALTHCARE OF THE RUSSIAN FEDERATION AND CIS COUNTRIES”
The participants of the conference have presented the following reports: Zaira Grigoryevna Kadagidze, Doctor of Medical Science, professor, head of Tumor Immunodiagnosis Department of the Research and Development Institute of Clinical Oncology of the Nikolai Blokhin Russian Cancer Research Center– “Immunomodulators in oncology. Refnot – new original domestic immunomodulator for palliative treatment of patients with malignant tumors”. Mikhail Evgenyevich Abramov, Candidate of Medical Science, the Department of Combined Treatment Methods and Chemotherapy of the Nikolai Blokhin Russian Cancer Research Center– “Modern aspects of tumor necrosis factor products application in the malignant tumor treatment. The results of the clinical study of Refnot”.
Date: 17-18 June 2014More...
The changes in Refnot product label are approved. The new proposed idication of Refnot is added: as an immunomodulator indisseminated melanoma treatment.
For treatment of disseminated melanoma Refnot is injected subcutaneously in the dosage of 100,000 units once daily, five times a week (then a two-days pause) or in the dosage of 400,000 units once a day, three times a week (every other day) during 2-4 weeks before chemotherapy. It is possible to inject the drug subcutaneously in the dosage of 400,000 units into one or several places, it is better to interchange the injection points. When administered without the subsequent chemotherapy, Refnot in injected subcutaneously in the dosage of 100, 000 units once daily, five times a week (then a two-days pause) during four weeks. If the disease does not progress, the product injection may be continued.
Date: December 24, 2012More...
The XI Nationwide Scientific and Practical Conference titled “Domestic Antitumor Products” dedicated to the 100th anniversary of N.N. Blokhin’s birth.
Nizhny Novgorod. The Senior scientific researcher of the Department of Combined Treatment Methods and Chemotherapy of the Nikolai Blokhin Russian Cancer Research Center of the Russian Academy of Medical Sciences, Candidate of Medical Science M. E. Abramov has presented a report titled “Refnot – the new immunomodulator to treat cancer patients”.
Date: 31.05 - 1.06 2012More...
The effect of REFNOT on the immunity in cancer patients
In the Nikolai Blokhin Russian Cancer Research Center of the Russian Academy of Medical Sciences, a report on postmarketing clinical study of REFNOT titled “The effect of REFNOT on the immunity in cancer patients” was prepared. The study included 55 patients with different solid tumors in disseminated stage of the disease. The oncologists of the Russian Academy of Medical Sciences recommend using REFNOT as an immunomodulator either solely or combined with cytostatic drugs in patients with malignant tumors.
Date: November 2011More...
XV Russian Oncological Congress
Moscow. The XV Russian Oncological Congress took place in the World Trade Center. Research and Production Enterprise Pharmaclone, LLC took part in pharmaceutical exhibition organized as a part of the congress.
Date: 15-17 November 2011More...
XIII Russian Oncological Congress
Nikolai Blokhin Russian Cancer Research Center of the Russian Academy of Medical Sciences, Moscow, held the XIII Russian Oncological Congress. Research and Production Enterprise Pharmaclone, LLC took part in pharmaceutical exhibition organized as a part of the congress.
Date: November 17-19, 2009More...
Open label controlled randomized II/III phase clinical study.
The N.N. Petrov Research and Development Institution of Oncology (Saint-Petersburg) has prepared an interim report on clinical study of REFNOT: Comparative randomized study of REFNOT combined with chemotherapy in the FEC mode, REFNOT combined with Ingaron and FEC chemotherapy, and FEC chemotherapy only in treatment of regional and metastatic breast cancer (phase II/III). The Institution oncologists reached a conclusion based on the results of the research: the FEC chemotherapy with REFNOT produced higher effecton the female patientsas compared to the reference group (FEC chemotherapy only).
Date: January 2009More...
The study of REFNOT safety, tolerability and effectiveness.
The Nikolai Blokhin Russian Cancer Research Center of the Russian Academy of Medical Sciences has prepared a report of a pivotal clinical study of REFNOT titled “The study of REFNOT safety, tolerability and effectivenessin patients with squamous cellcarcinoma of head and neck (I phase)”. 15 patients with malignant tumors of head or neck were included in the study. The oncologists have established good clinical and biological tolerability of REFNOT when it was injected intratumorally to the patients with squamous cell carcinoma of head and neck in a wide range of dosages.
Date: March 2005 г.More...